DE69534760D1 - Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen - Google Patents

Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen

Info

Publication number
DE69534760D1
DE69534760D1 DE69534760T DE69534760T DE69534760D1 DE 69534760 D1 DE69534760 D1 DE 69534760D1 DE 69534760 T DE69534760 T DE 69534760T DE 69534760 T DE69534760 T DE 69534760T DE 69534760 D1 DE69534760 D1 DE 69534760D1
Authority
DE
Germany
Prior art keywords
liposomes
liposome
therapeutic agents
luminal
sendai virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534760T
Other languages
English (en)
Inventor
J Dzau
Kaneda Yasufumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69534760D1 publication Critical patent/DE69534760D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69534760T 1994-05-10 1995-04-28 Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen Expired - Lifetime DE69534760D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/241,372 US5631237A (en) 1992-12-22 1994-05-10 Method for producing in vivo delivery of therapeutic agents via liposomes
PCT/US1995/005420 WO1995030330A1 (en) 1994-05-10 1995-04-28 Method for in vivo delivery of therapeutic agents via liposomes

Publications (1)

Publication Number Publication Date
DE69534760D1 true DE69534760D1 (de) 2006-04-13

Family

ID=22910461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534760T Expired - Lifetime DE69534760D1 (de) 1994-05-10 1995-04-28 Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen

Country Status (5)

Country Link
US (1) US5631237A (de)
EP (1) EP0759694B1 (de)
AT (1) ATE316333T1 (de)
DE (1) DE69534760D1 (de)
WO (1) WO1995030330A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
PT732929E (pt) 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6007838A (en) † 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
EP0906123A4 (de) * 1996-03-15 1999-05-26 Univ Florida ANGIOTENSINOGEN-mRNA SPEZIFISCHE OLIGONUKLEOTIDE
CZ299809B6 (cs) 1996-05-08 2008-12-03 Nika Health Products Limited Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE69736692T2 (de) * 1996-07-16 2007-06-14 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999015643A2 (en) * 1997-09-25 1999-04-01 University Of Florida ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
US6734171B1 (en) * 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6129757A (en) * 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US7241617B2 (en) * 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
EP1141364A1 (de) 1999-01-08 2001-10-10 Amaxa GmbH Ausnutzung zelleigener transportsysteme zum transfer von nukleinsäuren durch die kernhülle
WO2000058511A1 (en) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000059939A1 (en) * 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
WO2001013106A1 (en) * 1999-08-17 2001-02-22 Mayo Foundation For Medical Education And Research System for monitoring the expression and/or location of transgenes
WO2001017511A1 (en) * 1999-09-03 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Method of intracellular sustained-release of drug and preparations
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
WO2001043778A1 (en) * 1999-12-17 2001-06-21 Gene Therapy Systems, Inc. Use of cationic lipids for intracellular protein delivery
KR100774796B1 (ko) * 2000-01-19 2007-11-07 가부시키가이샤 디나벡크 겐큐쇼 파라믹소바이러스 벡터의 혈관으로의 유전자 도입용도
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
CA2418179A1 (en) * 2000-07-26 2002-01-31 University Of Maryland, Baltimore The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
EP1361896A2 (de) * 2001-01-23 2003-11-19 Boston Scientific Corporation Methode zur lokalen myocardialen injektion zur behandlung ischämischen myocardiums
US6497896B2 (en) 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2003014338A1 (en) * 2001-08-02 2003-02-20 Anges Mg, Inc. Process for producing inactivated virus envelope
US20040022727A1 (en) * 2002-06-18 2004-02-05 Martin Stanton Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
CA2497313A1 (en) * 2002-08-27 2004-04-29 Anges Mg, Inc. Biomolecule transfer method using virus envelope and composition and system therefor
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1566436A4 (de) * 2002-11-21 2006-04-19 Genomidea Inc Verfahren zur isolierung von nukleinsäure mit erwünschter funktioneller eigenschaft und kit dafür
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
DK1757312T3 (da) * 2004-06-14 2011-04-11 Ishihara Sangyo Kaisha Frysetørret sammensætning af inaktiveret viruskappe med membranfusionsaktivitet
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
EP1919944B1 (de) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US8691212B2 (en) 2008-09-16 2014-04-08 Genomldea Inc. Therapeutic/prophylactic agent for prostate cancer
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2012031137A2 (en) 2010-09-02 2012-03-08 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2012092341A1 (en) 2010-12-28 2012-07-05 University Of Rochester Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
AU2012255143A1 (en) 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
PT2785683T (pt) 2011-11-30 2020-04-16 Ludwig Inst For Cancer Res Ltd Moduladores de célula inkt e métodos para o seu uso
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
AU2013240248B2 (en) 2012-03-26 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Delivery of packaged RNA to mammalian cells
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
US9321749B1 (en) 2012-07-25 2016-04-26 Globavir Biosciences, Inc. Heterocyclic compounds and uses thereof
HUE054260T2 (hu) 2012-09-06 2021-08-30 Univ Chicago Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
EP2912178B1 (de) 2012-10-25 2020-06-17 Whitehead Institute For Biomedical Research Superverstärker und verfahren zur verwendung davon
WO2014125291A1 (en) 2013-02-14 2014-08-21 Ucl Business Plc Agents which induce lymphangiogenesis for use in the treatment of cystic kidney disease
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
WO2015024022A2 (en) 2013-08-16 2015-02-19 University Of Rochester Designed peptides for tight junction barrier modulation
CN106232807A (zh) 2013-12-16 2016-12-14 美利坚合众国, 由健康及人类服务部部长代表 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法
PT3283500T (pt) 2015-04-08 2021-01-28 Univ Chicago Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
EP3371211B1 (de) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-assoziierte proteinkinasehemmer zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
WO2018084185A1 (ja) 2016-11-01 2018-05-11 国立大学法人大阪大学 Ｈｖｊ－ｅおよび免疫チェックポイントタンパク質の阻害物質を含む抗がん剤
ES2896255T3 (es) 2016-12-06 2022-02-24 Univ Osaka Nuevo agente terapéutico para enfermedades por prionoides
MX2020008377A (es) 2018-03-27 2020-09-25 Enzyvant Therapeutics Gmbh Marcadores de la enfermedad de farber y usos de estos.
MX2020013450A (es) 2018-06-11 2021-08-11 Univ Florida Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés.
CA3103675A1 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20220088158A1 (en) 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
US20230057355A1 (en) 2019-02-13 2023-02-23 University Of Rochester Gene networks that mediate remyelination of the human brain
US20220249364A1 (en) 2019-06-05 2022-08-11 University Of Rochester Designed Inhibitors of Tight Junction Formation
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4262827A1 (de) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Behandlung von krebs mit tumorinfiltrierenden lymphozyten
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4426331A1 (de) 2021-11-02 2024-09-11 University of Rochester Tcf7l2-vermittelte remyelinisierung im gehirn
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
EP4658294A2 (de) 2023-02-02 2025-12-10 University of Rochester Kompetitiver ersatz von gliazellen
EP4704807A1 (de) 2023-05-03 2026-03-11 IOX Therapeutics Limited Liposomale inkt-zellmodulatorzusammensetzungen und verfahren zur verwendung
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules

Also Published As

Publication number Publication date
EP0759694A4 (de) 2000-11-08
ATE316333T1 (de) 2006-02-15
EP0759694A1 (de) 1997-03-05
WO1995030330A1 (en) 1995-11-16
US5631237A (en) 1997-05-20
EP0759694B1 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
ATE316333T1 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
ATE207738T1 (de) Verfahren zur baladung von lipidvesikeln
Sato et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice
ATE209902T1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
FI962799A0 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
DK0852490T3 (da) Emulsionsformuleringer til tilførsel af nukleinsyrer til celler
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
EA199700197A1 (ru) Стабильные белково-фосфолипидные составы и способы их получения
AU1724097A (en) Lipids and their use, for example, in liposomes
EP0986372A4 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
ATE511834T1 (de) Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en)
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
CA2259179A1 (en) Emulsion formulations for hydrophilic active agents
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
DE69624485D1 (de) Verfahren zur herstellung hydro-monobenzoporhyrin -photosensibilisatoren enthaltender liposomen
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
ATE362991T1 (de) Kondensierte plasmid-liposome komplex zur transfektion
ATE301709T1 (de) Lipidabkömmlinge von pentaerythritol
ATE194776T1 (de) Verfahren zur herstellung von lipid-konjugaten
WO2025174825A3 (en) Delivery compositions
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
NO951762L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff
WO1999065461A3 (en) Cationic amphiphile micellar complexes

Legal Events

Date Code Title Description
8332 No legal effect for de